Business Wire

Dfns Secures $16M to Expand its Crypto Wallet Infrastructure for Finance

14.1.2025 16:00:00 CET | Business Wire | Press release

Share

Dfns, the leading wallet-as-a-service platform for crypto assets, has successfully closed a $16 million Series A, led by Further Ventures, the venture arm of Abu Dhabi’s largest sovereign wealth fund, ADQ. This round also saw participation from historic investors such as White Star Capital, Hashed, Semantic, Techstars, and Bpifrance, alongside new backers including Motive Partners, Wintermute, and Motier Ventures.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114288142/en/

null

(Photo: Business Wire)

Our Institutional Focus Paid Off

Two years ago, Dfns made a strategic up-market move focusing mainly on institutional clients. The company’s vision has remained steadfast: institutional investors hold the key to driving crypto adoption as they have the lion’s share of the global liquidity. To appeal to them, Dfns prioritized uncompromising bank-grade security, aligning with standard traditional financial systems and leveraging state-of-the-art technology to surpass expectations. As crypto assets gain in value, the risks and scrutiny surrounding them grow. By positioning itself as the most secure blockchain wallet infrastructure, Dfns has become the infrastructure of choice for trusted institutions navigating crypto and shaping its future inside finance.

Dfns has a reputation for transparency, reliability and security, with trust-building initiatives: industry-leading certifications, regulatory licenses, robust insurance, independent audits, and partnerships with global leaders. Its hallmark clients include Fidelity, Bridge (Stripe), Zodia Custody (Standard Chartered), Tungsten Custody (ADQ), and 130+ fintechs worldwide.

Strategic Use of Funds

Following its $13 million seed round in 2022, this new Series A funding will enable Dfns to accelerate the distribution of its multichain wallet infrastructure in 2025. The focus will be on expanding adoption among banks, payment services, trading platforms, investment apps, tokenization projects, government and corporate treasuries, and fund administrators, with an emphasis on the EU, UK, UAE, and US markets.

“We have a clear plan,” said Clarisse Hagège, CEO of Dfns. “Crypto can be unpredictable, so we’ve learned to prioritize sustainable growth over rapid expansion. We’re not looking to scale our workforce aggressively; instead, we aim to grow from 25 to 35 employees by year-end, provided we meet our targets and the market remains stable. Our focus is to deliver world-class infrastructure for our fintech clients. They demand bank-grade security, smarter transaction management, direct integrations, and better user and developer experiences. This is what we do best, and it’s what we’ll keep delivering.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114288142/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye